BioStar Capital is a value-add investment firm focused on transformational medical device technologies in cardiovascular and orthopaedic medicine. Combining the insight of experienced investment professionals and world-renowned medical thought leaders, BioStar Capital identifies proprietary technologies that serve unmet patient needs and fit the acquisition criteria of leading medical device companies. BioStar Capital fills an important gap in medical device innovation and provides operational skills and clinical expertise in addition to capital, enabling the firm to actively mitigate risk, optimize product development, and secure successful exit. The firm has invested in over 30 med-tech companies, many of which have been acquired by a major medical device manufacturer.

BioStar News
Portfolio News

September 15, 2020

Mark Toland, Former CEO of Siemens-Owned Corindus, Joins BioStar Capital as Partner and Entrepreneur in Residence

>> Read More

July 14, 2019

BioStar Capital Expands VC Fund to $91 Million

>> Read More

October 13, 2020

Foldax Named Cardiovascular Device Company of the Year by MedTech Outlook

>> Read More

October 7, 2020

Foldax Strengthens Scientific and Medical Advisory Boards

>> Read More

Active Portfolio Companies
ASI Logo - New.png
Trice Logo - New.png